Actinogen Medical - XanaCIDD data narrow the focus in depression
While the results from Actinogen’s XanaCIDD exploratory Phase IIa study in patients with major depressive disorder (MDD) did not meet the primary endpoint in terms of improving cognitive impairment (CI) symptoms, they did show signs of efficacy in terms of treating depression symptoms. Notably, a statistically significant improvement was reported at four weeks after the six-week treatment period. The company’s strategy in MDD will now focus on treating depression symptoms and Actinogen will investigate the path forward for a Phase IIb trial that could start as early as H2 CY25. As our model now reflects the larger target market of treating symptoms of depression (versus CI) in MDD, our risk-adjusted net present value rises to A$603m (vs A$544m previously).Actinogen Medical is engaged in the undertaking of research of biological material obtained from field work and samples obtained from external sources for commercial applications. Co. operates predominantly in Australia.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.